Wells Fargo analyst Jim Birchenough raised his price target for uniQure to $65 from $51 following strong preclinical data update for its AMT-130 Huntington’s gene silencing candidate. With recent validation from RNA therapeutic intervention, the analyst views the category as one of the largest in the BioPharma space and believes preclinical data bodes well for clinical success. He reiterates an Outperform rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.